Literature DB >> 14713908

Development of the asthma control test: a survey for assessing asthma control.

Robert A Nathan1, Christine A Sorkness, Mark Kosinski, Michael Schatz, James T Li, Philip Marcus, John J Murray, Trudy B Pendergraft.   

Abstract

BACKGROUND: Asthma guidelines indicate that the goal of treatment should be optimum asthma control. In a busy clinic practice with limited time and resources, there is need for a simple method for assessing asthma control with or without lung function testing.
OBJECTIVES: The objective of this article was to describe the development of the Asthma Control Test (ACT), a patient-based tool for identifying patients with poorly controlled asthma.
METHODS: A 22-item survey was administered to 471 patients with asthma in the offices of asthma specialists. The specialist's rating of asthma control after spirometry was also collected. Stepwise regression methods were used to select a subset of items that showed the greatest discriminant validity in relation to the specialist's rating of asthma control. Internal consistency reliability was computed, and discriminant validity tests were conducted for ACT scale scores. The performance of ACT was investigated by using logistic regression methods and receiver operating characteristic analyses.
RESULTS: Five items were selected from regression analyses. The internal consistency reliability of the 5-item ACT scale was 0.84. ACT scale scores discriminated between groups of patients differing in the specialist's rating of asthma control (F = 34.5, P <.00001), the need for change in patient's therapy (F = 40.3, P <.00001), and percent predicted FEV(1) (F = 4.3, P =.0052). As a screening tool, the overall agreement between ACT and the specialist's rating ranged from 71% to 78% depending on the cut points used, and the area under the receiver operating characteristic curve was 0.77.
CONCLUSION: Results reinforce the usefulness of a brief, easy to administer, patient-based index of asthma control.

Entities:  

Mesh:

Year:  2004        PMID: 14713908     DOI: 10.1016/j.jaci.2003.09.008

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  682 in total

1.  The real-life clinical effects of 52 weeks of omalizumab therapy for severe persistent allergic asthma.

Authors:  Caroline Gouder; Lorna Marie West; Stephen Montefort
Journal:  Int J Clin Pharm       Date:  2014-11-14

2.  Differences in Environmental Control and Asthma Outcomes Among Urban Latino, African American, and Non-Latino White Families.

Authors:  Robin S Everhart; Sheryl Kopel; Elizabeth L McQuaid; Leslie Salcedo; Daniel York; Christina Potter; Daphne Koinis-Mitchell
Journal:  Pediatr Allergy Immunol Pulmonol       Date:  2011-09       Impact factor: 1.349

3.  [Treatment strategies for asthma].

Authors:  S Korn; C Taube; R Buhl
Journal:  Internist (Berl)       Date:  2012-04       Impact factor: 0.743

4.  Identifying individual, cultural and asthma-related risk and protective factors associated with resilient asthma outcomes in urban children and families.

Authors:  Daphne Koinis-Mitchell; Elizabeth L McQuaid; Barbara Jandasek; Sheryl J Kopel; Ronald Seifer; Robert B Klein; Christina Potter; Gregory K Fritz
Journal:  J Pediatr Psychol       Date:  2012-03-09

5.  Allergic rhinitis quality of life in urban children with asthma.

Authors:  Robin S Everhart; Sheryl J Kopel; Cynthia A Esteban; Elizabeth L McQuaid; Robert Klein; Christine E McCue; Daphne Koinis-Mitchell
Journal:  Ann Allergy Asthma Immunol       Date:  2014-02-28       Impact factor: 6.347

6.  Performance of the Asthma Impact on Quality of Life Scale (A-IQOLS) in diverse asthma research populations and demographic subgroups.

Authors:  Sandra R Wilson; Robert A Wise; Mario Castro; Michael J Mulligan; Estela Ayala; Alan Chausow; Qiwen Huang; Santosh Gummidipundi
Journal:  J Allergy Clin Immunol       Date:  2018-05-04       Impact factor: 10.793

7.  A 12-week, Randomized, Parallel-group, Phase III Study Comparing the Efficacy of Once-daily Budesonide/formoterol Turbuhaler (160/4.5 μg/d) with Twice-daily Budesonide (400 μg/d) During the Step-down Period in Well-controlled Asthma.

Authors:  Narongwit Nakwan; Thitima Perkleang; Thanida Tamsawai; Pattarawadee Taptawee; Sirikade Usaha
Journal:  Turk Thorac J       Date:  2018-04-01

8.  The influence of psychosocial stressors and socioeconomic status on sleep among caregivers of teenagers with asthma, the Puff City study.

Authors:  Dayna A Johnson; Lisa J Meltzer; Talan Zhang; Mei Lu; Andrea E Cassidy-Bushrow; Stephanie Stokes-Buzzelli; Elizabeth Duffy; Brittany McKinnon; Prashant Mahajan; Susan Redline; Christine Lm Joseph
Journal:  Sleep Health       Date:  2017-12-19

9.  Fractional Exhaled Nitric Oxide-Assisted Management of Uncontrolled Persistent Asthma: A Real-World Prospective Observational Study.

Authors:  Robert Stephen Zeiger; Michael Schatz; Su-Jau Yang; Wansu Chen
Journal:  Perm J       Date:  2019

10.  Longitudinal validation of a tool for asthma self-monitoring.

Authors:  Flory L Nkoy; Bryan L Stone; Bernhard A Fassl; Derek A Uchida; Karmella Koopmeiners; Sarah Halbern; Eun H Kim; Allison Wilcox; Jian Ying; Tom H Greene; David M Mosen; Michael N Schatz; Christopher G Maloney
Journal:  Pediatrics       Date:  2013-11-11       Impact factor: 7.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.